X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7175) 7175
Publication (1284) 1284
Book Review (79) 79
Newspaper Article (33) 33
Conference Proceeding (15) 15
Book Chapter (13) 13
Dissertation (9) 9
Book / eBook (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5045) 5045
index medicus (3877) 3877
animals (3317) 3317
cell cycle (1914) 1914
mice (1890) 1890
apoptosis (1791) 1791
cyclin-dependent kinases - antagonists & inhibitors (1676) 1676
cell line, tumor (1670) 1670
oncology (1651) 1651
phosphorylation (1619) 1619
cancer (1596) 1596
cell biology (1558) 1558
biochemistry & molecular biology (1425) 1425
cyclin-dependent kinases (1422) 1422
female (1338) 1338
expression (1225) 1225
proteins (1156) 1156
kinases (1086) 1086
male (1085) 1085
cell proliferation - drug effects (1002) 1002
apoptosis - drug effects (998) 998
cyclin-dependent kinases - metabolism (937) 937
signal transduction (914) 914
cyclin-dependent kinase inhibitor p21 - metabolism (851) 851
cell proliferation (843) 843
protein kinase inhibitors - pharmacology (827) 827
research (827) 827
antineoplastic agents - pharmacology (826) 826
cells, cultured (787) 787
gene expression (784) 784
cell cycle - drug effects (767) 767
activation (759) 759
enzyme inhibitors - pharmacology (756) 756
article (747) 747
cyclin-dependent kinase inhibitor p21 (738) 738
rats (714) 714
tumor suppressor protein p53 - metabolism (664) 664
proliferation (627) 627
cyclin-dependent kinase inhibitor p27 (613) 613
cell line (612) 612
analysis (596) 596
tumor cells, cultured (586) 586
signal transduction - drug effects (582) 582
multidisciplinary sciences (573) 573
research article (568) 568
cyclin-dependent kinase inhibitor p21 - genetics (563) 563
cell-cycle (550) 550
p53 (549) 549
cyclins - metabolism (545) 545
pharmacology & pharmacy (539) 539
cyclin-dependent kinase (535) 535
blotting, western (530) 530
cyclin-dependent kinase 4 (529) 529
growth (528) 528
tumors (522) 522
inhibition (520) 520
cyclin-dependent kinase 2 (501) 501
mutation (487) 487
protein (485) 485
medicine (471) 471
down-regulation (464) 464
p21 (463) 463
genetic aspects (459) 459
cell cycle proteins - metabolism (458) 458
biology (455) 455
cell growth (454) 454
in-vitro (454) 454
cyclin-dependent kinase 4 - antagonists & inhibitors (447) 447
dose-response relationship, drug (440) 440
breast cancer (430) 430
rna interference (423) 423
in-vivo (422) 422
transfection (422) 422
chemistry, medicinal (420) 420
protein-serine-threonine kinases - metabolism (418) 418
health aspects (416) 416
p27 (405) 405
physiological aspects (405) 405
care and treatment (403) 403
protein binding (402) 402
cyclin-dependent kinase inhibitor p27 - metabolism (398) 398
retinoblastoma protein - metabolism (397) 397
phosphorylation - drug effects (390) 390
tumor suppressor protein p53 - genetics (390) 390
cell survival - drug effects (387) 387
cells (387) 387
gene-expression (387) 387
inhibitors (378) 378
cell cycle proteins (374) 374
science (373) 373
purines - pharmacology (366) 366
cyclin d1 - metabolism (362) 362
gene expression regulation, neoplastic (361) 361
protein-serine-threonine kinases - antagonists & inhibitors (361) 361
transcription (349) 349
neurosciences (348) 348
structure-activity relationship (347) 347
differentiation (344) 344
cyclin-dependent kinase 2 - metabolism (341) 341
middle aged (341) 341
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7192) 7192
Chinese (9) 9
French (8) 8
German (6) 6
Japanese (6) 6
Russian (2) 2
Czech (1) 1
Korean (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Cancer, ISSN 1474-175X, 01/2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2016, Volume 6, Issue 4, pp. 353 - 367
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2014, Volume 26, Issue 1, pp. 136 - 149
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have... 
DRUG | INACTIVATION | ADVANCED SOLID TUMORS | MAMMARY-TUMORS | GENE | ONCOLOGY | PATHWAY INHIBITORS | CYCLIN D1 EXPRESSION | GROWTH | PHASE-I | PRECLINICAL EVALUATION | CELL BIOLOGY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Phosphatidylinositol Phosphates - metabolism | Cyclin-Dependent Kinase 4 - genetics | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | MCF-7 Cells | RNA Interference | Time Factors | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - drug effects | Genetic Predisposition to Disease | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Phenotype | Animals | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Signal Transduction - drug effects | Breast Neoplasms - pathology | Mice, Nude | Cell Proliferation - drug effects | Mice | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Medical colleges | Breast cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2015, Volume 21, Issue 5, pp. 995 - 1001
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4055 - 4065
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-positive (ER+) breast cancer. This single-arm phase II neoadjuvant... 
TRIAL | AROMATASE INHIBITOR | 1ST-LINE TREATMENT | RETINOBLASTOMA PROTEIN | ONCOLOGY | INTRINSIC SUBTYPE | IN-VIVO | DOUBLE-BLIND | LETROZOLE | CELL-PROLIFERATION | POSTMENOPAUSAL WOMEN | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Breast Neoplasms - surgery | Triazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Pyridines - adverse effects | Adult | Female | Neoadjuvant Therapy | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Neoplasm Staging | Cell proliferation | Anastrozole | Estrogens | Cyclin-dependent kinases | Estrogen | Estrogen receptors | Breast cancer | Kinases | Gene expression | Patients | ErbB-2 protein | Cyclin-dependent kinase 4 | Cyclin-dependent kinase | E2F protein | Inhibitors | Experimental design | Surgery | Cell cycle | Breast | Cancer | breast cancer | neoadjuvant | anastrozole | CDK4 | palbociclib
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2017, Volume 109, Issue 5
Journal Article